T-1301 Phase I clinical trial is to be initiated in Mid-December, 2021 in multiple centers in Taiwan. T-1301 is a small molecular multi-target tyrosine kinase inhibitor (TKI), exhibiting potential of multiple anti-cancer indications. The Phase I trial is to evaluate safety and tolerability of T-1301, the recommended Phase 2 dose (RP2D), and the pharmacokinetics in human, and to assess the preliminary anti-tumor activities of T-1301.
News
News
T-1301 Phase I clinical trial is to be initiated in Mid-December, 2021